This mAb showed robust and dose-dependent CD138 engagement to MM cell lines and patient-derived MM cells, as well as target-specific ADCC mediated by NK cells and macrophages against MM cell lines and autologous patient cells. Here, SDC1 is linked to Miyoshi myopathy.